PortfoliosLab logoPortfoliosLab logo
CPRX vs. CROX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CPRX vs. CROX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Catalyst Pharmaceuticals, Inc. (CPRX) and Crocs, Inc. (CROX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CPRX achieves a 34.02% return, which is significantly lower than CROX's 41.08% return. Over the past 10 years, CPRX has outperformed CROX with an annualized return of 48.01%, while CROX has yielded a comparatively lower 27.39% annualized return.


CPRX

1D
0.03%
1M
0.42%
YTD
34.02%
6M
35.06%
1Y
20.91%
3Y*
39.11%
5Y*
40.76%
10Y*
48.01%

CROX

1D
1.09%
1M
16.42%
YTD
41.08%
6M
39.95%
1Y
18.91%
3Y*
1.26%
5Y*
2.78%
10Y*
27.39%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CPRX vs. CROX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CPRX
Catalyst Pharmaceuticals, Inc.
34.02%11.84%24.15%-9.62%174.74%102.69%-10.93%95.31%-50.90%272.38%
CROX
Crocs, Inc.
41.08%-21.92%17.26%-13.85%-15.43%104.63%49.58%61.24%105.54%84.26%

Correlation

The correlation between CPRX and CROX is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.23

Correlation (3Y)
Calculated over the trailing 3-year period

0.26

Correlation (5Y)
Calculated over the trailing 5-year period

0.29

Correlation (10Y)
Calculated over the trailing 10-year period

0.24

Correlation (All Time)
Calculated using the full available price history since Nov 9, 2006

0.17

The correlation between CPRX and CROX shifts across timeframes, from 0.17 (all time) to 0.29 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

CPRX:

$3.97B

CROX:

$6.12B

EPS

CPRX:

$1.74

CROX:

-$1.94

PS Ratio

CPRX:

6.67

CROX:

1.60

PB Ratio

CPRX:

3.92

CROX:

4.29

Total Revenue (TTM)

CPRX:

$596.96M

CROX:

$4.02B

Gross Profit (TTM)

CPRX:

$378.23M

CROX:

$2.34B

EBITDA (TTM)

CPRX:

$313.50M

CROX:

$297.04M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CPRX vs. CROX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CPRX
CPRX Risk / Return Rank: 5959
Overall Rank
CPRX Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
CPRX Sortino Ratio Rank: 5757
Sortino Ratio Rank
CPRX Omega Ratio Rank: 5757
Omega Ratio Rank
CPRX Calmar Ratio Rank: 5959
Calmar Ratio Rank
CPRX Martin Ratio Rank: 5757
Martin Ratio Rank

CROX
CROX Risk / Return Rank: 5454
Overall Rank
CROX Sharpe Ratio Rank: 5555
Sharpe Ratio Rank
CROX Sortino Ratio Rank: 5252
Sortino Ratio Rank
CROX Omega Ratio Rank: 5555
Omega Ratio Rank
CROX Calmar Ratio Rank: 5555
Calmar Ratio Rank
CROX Martin Ratio Rank: 5353
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CPRX vs. CROX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and Crocs, Inc. (CROX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CPRXCROXDifference
Sharpe ratioReturn per unit of total volatility

+0.26

Sortino ratioReturn per unit of downside risk

+0.25

Omega ratioGain probability vs. loss probability

1.14

1.13

+0.01

Calmar ratioReturn relative to maximum drawdown

0.77

0.58

+0.19

Martin ratioReturn relative to average drawdown

1.40

0.99

+0.41

CPRX vs. CROX - Sharpe Ratio Comparison

The current CPRX Sharpe Ratio is 0.63, which is higher than the CROX Sharpe Ratio of 0.36. The chart below compares the historical Sharpe Ratios of CPRX and CROX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


CPRXCROXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.63

0.36

+0.26

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.86

0.05

+0.81

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.80

0.49

+0.31

Sharpe Ratio (All Time)

Calculated using the full available price history

0.09

0.17

-0.08

Drawdowns

CPRX vs. CROX - Drawdown Comparison

The maximum CPRX drawdown since its inception was -94.25%, roughly equal to the maximum CROX drawdown of -98.74%. Use the drawdown chart below to compare losses from any high point for CPRX and CROX.


Loading charts...

Drawdown Indicators


CPRXCROXDifference

Max Drawdown

Largest peak-to-trough decline

-94.25%

-98.74%

+4.49%

Max Drawdown (1Y)

Largest decline over 1 year

-27.29%

-32.54%

+5.25%

Max Drawdown (3Y)

Largest decline over 3 years

-27.29%

-54.04%

+26.75%

Max Drawdown (5Y)

Largest decline over 5 years

-45.37%

-73.86%

+28.49%

Max Drawdown (10Y)

Largest decline over 10 years

-64.87%

-75.18%

+10.31%

Current Drawdown

Current decline from peak

-0.16%

-33.18%

+33.02%

Average Drawdown

Average peak-to-trough decline

-52.02%

-61.28%

+9.26%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.95%

19.17%

-4.22%

Volatility

CPRX vs. CROX - Volatility Comparison

The current volatility for Catalyst Pharmaceuticals, Inc. (CPRX) is 0.44%, while Crocs, Inc. (CROX) has a volatility of 11.01%. This indicates that CPRX experiences smaller price fluctuations and is considered to be less risky than CROX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CPRXCROXDifference

Volatility (1M)

Calculated over the trailing 1-month period

0.44%

11.01%

-10.57%

Volatility (6M)

Calculated over the trailing 6-month period

23.50%

31.82%

-8.32%

Volatility (1Y)

Calculated over the trailing 1-year period

33.58%

52.52%

-18.94%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

47.80%

55.12%

-7.32%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

60.47%

55.96%

+4.51%

Dividends

CPRX vs. CROX - Dividend Comparison

Neither CPRX nor CROX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

CPRX vs. CROX - Financials Comparison

This section allows you to compare key financial metrics between Catalyst Pharmaceuticals, Inc. and Crocs, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B1.20B20222023202420252026
149.39M
921.46M
(CPRX) Total Revenue
(CROX) Total Revenue
Values in USD except per share items

CPRX vs. CROX - Profitability Comparison

The chart below illustrates the profitability comparison between Catalyst Pharmaceuticals, Inc. and Crocs, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%202220232024202520260
56.8%
Portfolio components
CPRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.

CROX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Crocs, Inc. reported a gross profit of 522.95M and revenue of 921.46M. Therefore, the gross margin over that period was 56.8%.

CPRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.

CROX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Crocs, Inc. reported an operating income of 200.84M and revenue of 921.46M, resulting in an operating margin of 21.8%.

CPRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.

CROX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Crocs, Inc. reported a net income of 137.56M and revenue of 921.46M, resulting in a net margin of 14.9%.


Frequently Asked Questions


CPRX and CROX have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CROX has higher volatility (11.01%) compared to CPRX (0.44%). In terms of maximum drawdown, CPRX dropped -94.25% vs CROX's -98.74%.

CPRX currently has the higher Sharpe Ratio (0.63 vs 0.36), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CPRX and CROX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer